1801.HK
INNOVENT BIO
HK$80.90
-2.94%
2026-06-01
About INNOVENT BIO
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Key Fundamentals
P/E Ratio
154.35
Forward P/E
31.20
EPS (TTM)
HK$0.54
ROE
5.0%
Revenue Growth (YoY)
29.6%
Profit Margin
6.2%
Debt/Equity
14.55
Price/Book
6.46
Beta
0.24
Market Cap
HK$144.58B
Avg Volume (10D)
16.6M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
HK$93.80
60D Low
HK$74.60
Avg Volume
12.9M
Latest Close
HK$80.90
Get breakout alerts for 1801.HK
Sign up for Breakout Scanner to receive daily notifications when 1801.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
INNOVENT BIO (1801.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 1801.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 1801.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.